Program – Full Style

Caption Lines Here
Day 1
06 May 2019

Fireside Chat with Mark McClellan and Scott Gottlieb

Fireside Chat with Two Former FDA Commissioners Scott Gottlieb, M.D., Resident Fellow on Health Policy Studies, The American Enterprise Institute Mark McClellan, M.D., Ph.D., Robert J. Margolis Professor of Business,...
Read More
Crystal Pike
Crystal Pike
Mark McClellan
Mark McClellan
Scott Gottlieb
Scott Gottlieb
10:45 am - 11:00 am

Email/Coffee Break

Why Has the US Biosimilar Experience Not Yet Lived Up to the Hype?

Biosimilar patent and antitrust litigation has been heating up over the past five years. When the first biosimilar was approved in the US in 2015, many health care observers eagerly...
Read More
Carla Mulhern
Carla Mulhern
Richard Mortimer
Richard A. Mortimer
Tony LoSasso
Anthony T. LoSasso
Paul Greenberg
Paul E. Greenberg

How Are Cutting-Edge Analytical Methods Being Used in Life Sciences Litigation?

Experiments, natural experiments, conjoint analysis, modern survey research, machine learning, and natural language processing: these sophisticated tools have all been used in innovative ways in life sciences litigation, including calculating...
Read More
Mihran Yenikomshian
Mihran Yenikomshian
Jimmy Royer
Jimmy Royer
Lisa Pinheiro
Lisa B. Pinheiro
Natalie Mizik
Natalie Mizik
Joseph Doyle
Joseph Doyle
Rene Befurt
Rene Befurt

Controlling the Cost of Pharmaceuticals – At What Price? A Discussion of the Economics of Drug Pricing

The pricing of innovative medicines is a galvanizing issue on the political campaign trail, on newspaper editorial pages, in negotiations between manufacturers and pharmacy benefits managers, and in litigation. Innovation...
Read More
Noam Kirson
Noam Kirson
Scott Gottlieb
Scott Gottlieb
Craig Garthwaite
Craig Garthwaite
David Cutler
David Cutler
Rena Conti
Rena Conti
Jennifer Bryant
Jennifer Bryant
1:30 pm - 1:45 pm

Email/Coffee Break

Pill Power: The Economics of Monopolization Claims in Pharmaceutical Markets

While delayed generic entry cases dominated the pharmaceutical antitrust docket in the early part of this decade, there is now a broader mix of cases that evaluate competition in pharmaceutical...
Read More
Amanda Starc
Amanda Starc
Matthew Silversten
Matthew Silversten
Divya Mathur
Divya Mathur
Mark Duggan
Mark Duggan
Jeff Cohen
Jeffrey A. Cohen

Product Liability Litigation Involving Pharmaceuticals and Medical Devices: How Has It Changed in the Big Data/Social Media Era?

With the increased availability of published data and social media reports detailing patient outcomes and serious adverse events, product liability matters have become qualitative and quantitative quagmires for companies in...
Read More
Aaron Yeater
Aaron Yeater
Carlton Wessel
Carlton Wessel
Bruce Strombom
Bruce A. Strombom
Robert Platt
Robert Platt
Mei Sheng Duh
Mei Sheng Duh

Materiality, Causation, and Damages, Oh My! Where Are False Claims Act/Anti-Kickback Statute Cases Headed?

The False Claims Act and Anti-Kickback Statute have been key enforcement tools for the government and relators’ bar for the past decade, with health care fraud recoveries surpassing $2 billion...
Read More
Lou Rossiter
Louis F. Rossiter
Brad Rice
Brad Rice
Crystal Pike
Crystal Pike
Jonathan Ketcham
Jonathan Ketcham
Anupam Jena
Anupam B. Jena
Toni Citera
Toni-Ann Citera
Day 2
02 Oct 2019
11:00 am-11:30 am

Registration

12:30 pm-2:00 pm

Networking Lunch

Day 3
08 Jun 2020